 Windtree Therapeutics Inc NASDAQ:WINT shares are trading higher by 32 at 2.63 in Fridays premarket session after Oppenheimer initiated coverage on the stock with an Outperform rating and an 8 price target. Windtree Therapeutics is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. 